MSN Labs launches CabolongTM
- MSN Labs launches CabolongTM - country's first branded generic of Cabozantinib for treatment of renal cell carcinoma
The division will focus on presenting a comprehensive range of affordable High quality, Bio-Equivalent generic oncology medicines benefitting patients in India. MSN already holds a distinguished track record of launching early branded generics of 14 Oncology molecules and making its presence felt in the US, Europe and emerging markets.
This initiative comes at a crucial juncture wherein the cancer cases in the country are likely to increase to 15.6 lakhs by 2025 — a 12% increase from current estimated cases — based on current trends, according to the National Cancer Registry Programme Report 2020.
“Our endeavour at MSN Labs has always been to enable swift access to affordable life-saving medicines in critical therapeutic domains. Given the rising cancer incidence in our country and overwhelming treatment costs associated with it, launch of our dedicated oncology division demonstrates our unwavering commitment to patients’ health and economic well-being.” MSN Group commented on the occasion.
CabolongTM, available in 20mg/40mg/60mg strengths at the most affordable pricing of below INR 10,000 (Ten Thousand Rupees) for monthly treatment regimen with the highest strength, will hugely benefit Indian patients. The same therapy presently runs into Lakhs with imported brands currently available in the market.
CabolongTM is manufactured at MSN Labs’ state-of-the-art facility approved by stringent global regulatory authorities like US FDA and EU GMP. Recognized as the most innovative company to launch new molecules at affordable prices, MSN Labs also has an established presence in major therapeutic segments like Cardiology, Diabetology, Pain, CNS, Urology and Gastroenterology, etc.
